Compare TSCO & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSCO | DGX |
|---|---|---|
| Founded | 1938 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3B | 23.1B |
| IPO Year | 1996 | 1996 |
| Metric | TSCO | DGX |
|---|---|---|
| Price | $34.64 | $189.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 13 |
| Target Price | $53.05 | ★ $214.38 |
| AVG Volume (30 Days) | ★ 8.5M | 903.9K |
| Earning Date | 04-21-2026 | 04-21-2026 |
| Dividend Yield | ★ 2.76% | 1.82% |
| EPS Growth | 0.98 | ★ 13.78 |
| EPS | 2.06 | ★ 2.24 |
| Revenue | ★ $15,524,046,000.00 | $11,035,000,000.00 |
| Revenue This Year | $7.32 | $7.53 |
| Revenue Next Year | $6.01 | $3.77 |
| P/E Ratio | ★ $16.80 | $84.32 |
| Revenue Growth | 4.31 | ★ 11.78 |
| 52 Week Low | $34.37 | $164.65 |
| 52 Week High | $63.99 | $213.50 |
| Indicator | TSCO | DGX |
|---|---|---|
| Relative Strength Index (RSI) | 16.90 | 38.39 |
| Support Level | N/A | $176.61 |
| Resistance Level | $56.04 | $193.04 |
| Average True Range (ATR) | 1.32 | 5.42 |
| MACD | -0.82 | -0.38 |
| Stochastic Oscillator | 2.15 | 6.15 |
Tractor Supply is the largest operator of retail farm and ranch stores in the United States. The company targets recreational farmers and ranchers and has little exposure to commercial and industrial farm operations. Currently, the company operates 2,395 of its namesake banners in 49 states, along with 207 Petsense by Tractor Supply stores. Stores are generally concentrated in rural communities rather than urban and suburban areas. In fiscal 2025, revenue consisted primarily of livestock, equine & agriculture (around 30%), companion animal (25%), and seasonal & recreation (around 25%).
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.